Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)

NCT03290508 is registered in ClinicalTrials.gov with Myriad Genetic Laboratories, Inc. as lead sponsor.

NCT NCT03290508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03290508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)
Lead sponsor
Myriad Genetic Laboratories, Inc.
Phase
Observational
Overall status
Terminated
Start date
September 14, 2017
Completion date
January 14, 2022
Enrollment
524 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer